Optimal drug therapy for the suppression of ventricular arrhythmias in Andersen-Tawil syndrome and multifocal ectopic Purkinje-related premature contractions: a series of N-of-1 trials

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510682-42-01

Enrollment

Registered

2024-06-10

Start date

2025-08-13

Completion date

Unknown

Last updated

2024-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Andersen-Tawil syndrome, Multifocal Ectopic Purkinje-related Premature Contractions

Brief summary

The ventricular ectopy burden per 24-hour period.

Interventions

DRUGBISOPROLOL

DRUGMETOPROLOL

DRUGNEBIVOLOL

DRUGVERAPAMIL

DRUGQUINIDINE

DRUGPROPRANOLOL

DRUGFLECAINIDE

DRUGATENOLOL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The ventricular ectopy burden per 24-hour period.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026